Solara Active Pharma Sciences Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/v9ucumxdrer0n5dbbla92qe0.pdf

Key Takeaways


The Reset: Regulated Markets & Network Optimization

Pillai: "The urge for us to do that earlier and which also caused a lot of trouble for us has been removed by the fact that we have shut the tap from the Vizag facility."

Margins: A One-Off Dip, A Promised Recovery


CRAMS: The New Growth Vector


Ibuprofen: Normalized, Not Abandoned


Balance Sheet & Cash Flow


What Management Would Not Answer

Pillai: "As the law correctly calls itself The Biosecurity Act, this is only relevant to biologics, and it is not so relevant to Solara."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenueINR1,400–1,500 croresFY25
Full-year EBITDAINR230–260 croresFY25
Exit-quarter EBITDAINR80–90 crores (~20–22% margin)Q4 FY25
Gross margin recoveryBack to 48%H2 FY25
Year-end debtBelow INR500 crores (adjusted for uncalled rights)FY25-end
Debt-to-EBITDAComfortably under 2xFY25-end
Free cash generationAt least INR100 crores above guided EBITDAFY25
CRAMS growthGrow to ~10% of businessNext year
Vizag retrofitting capexNo additional borrowing requiredDuring retrofit

Key Metrics

MetricQ1 FY25
Revenue21% QoQ growth
Full-year revenue guidance₹1,400 cr to ₹1,500 cr
Reported EBITDA₹42 cr
Adjusted EBITDA₹50 cr, adjusted for one-time costs related to Vizag mothballing and R&D
Adjusted EBITDA margin~14%
Reported EBITDA growth276% QoQ
Full-year EBITDA guidance₹230 cr to ₹260 cr
Exit Q4 EBITDA guidance₹80 cr to ₹90 cr, approximately 20% to 22% margin
Gross margin48% (adjusted, Q4 FY24); expected to return to 48% in H2 FY25 after inventory reduction dip
Debt reduction₹160 cr in Q1, of which ₹40 cr from free cash generation
Year-end debt targetUnder ₹500 cr, adjusted for uncalled rights issue money
Debt to EBITDA guidanceUnder 2x
Regulated markets revenue share75% and above
CRAMS revenue contribution5% to 8% of revenue, expected to grow to about 10% next year
Vizag facility investmentAbout ₹600 cr
Pondicherry Ibuprofen capacityApproximately 5,000 tons, running fully occupied